[HTML][HTML] Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
[HTML][HTML] Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label …
LM Yu, M Bafadhel, J Dorward, G Hayward, BR Saville… - The Lancet, 2021 - thelancet.com
Background A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
[HTML][HTML] Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised …
Background Azithromycin, an antibiotic with potential antiviral and anti-inflammatory
properties, has been used to treat COVID-19, but evidence from community randomised …
properties, has been used to treat COVID-19, but evidence from community randomised …
[HTML][HTML] Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled …
Background Doxycycline is often used for treating COVID-19 respiratory symptoms in the
community despite an absence of evidence from clinical trials to support its use. We aimed …
community despite an absence of evidence from clinical trials to support its use. We aimed …
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
J Dorward, LM Yu, G Hayward, BR Saville… - British Journal of …, 2022 - bjgp.org
Background Colchicine has been proposed as a COVID-19 treatment. Aim To determine
whether colchicine reduces time to recovery and COVID-19-related admissions to hospital …
whether colchicine reduces time to recovery and COVID-19-related admissions to hospital …
[HTML][HTML] Consultations for clinical features of possible cancer and associated urgent referrals before and during the COVID-19 pandemic: an observational cohort …
BD Nicholson, JM Ordóñez-Mena, S Lay-Flurrie… - British journal of …, 2022 - nature.com
Background It remains unclear to what extent reductions in urgent referrals for suspected
cancer during the COVID-19 pandemic were the result of fewer patients attending primary …
cancer during the COVID-19 pandemic were the result of fewer patients attending primary …
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
PRINCIPLE Collaborative Group, LM Yu, M Bafadhel… - Medrxiv, 2021 - medrxiv.org
BACKGROUND Inhaled budesonide has shown efficacy for treating COVID-19 in the
community but has not yet been tested in effectiveness trials. METHODS We performed a …
community but has not yet been tested in effectiveness trials. METHODS We performed a …
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial …
G Hayward, CC Butler, LM Yu, BR Saville, N Berry… - BMJ open, 2021 - bmjopen.bmj.com
Introduction There is an urgent need to idenfy treatments for COVID-19 that reduce illness
duration and hospital admission in those at higher risk of a longer illness course and …
duration and hospital admission in those at higher risk of a longer illness course and …
d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial
Importance Recurrent urinary tract infection (UTI) is a common debilitating condition in
women, with limited prophylactic options. d-Mannose has shown promise in trials based in …
women, with limited prophylactic options. d-Mannose has shown promise in trials based in …
[HTML][HTML] Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been
elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 …
elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 …